Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Frequency: Typically 3 treatments 4-6 weeks apart, then maintenance treatments every 4-6 months
*Correspondence: Merridee A
Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 119.00 per year only 9.92 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Your provider at Allure Esthetic will review your medical history, goals, and several other factors to determine which medication may work best for you
Necroptosis A programmed form of necrosis that is downstream of cell-death receptor signalling, which is generally induced by cell damage but can also be promoted by lysosomal membrane permeabilization
US$ 28.44
US$ 21.40
US$ 28.37
